ESR1 and breast cancer: We have previously reported sensitive detection of ESR1 mutations using droplet-digital PCR (ddPCR) in 7% (3/43) primary ER-positive breast cancers, and in 24% (7/29) cfDNA samples collected from patients with recurrent disease [14].